Valeant Pharmaceuticals, based in Laval, Quebec, has announced plans to sell $1.75 billion in stock to support its acquisition of Bausch + Lomb, according to a PharmaLive report.
Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company's debt.
Valeant did not disclose the number of shares it plans to sell.
More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout
Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company's debt.
Valeant did not disclose the number of shares it plans to sell.
More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout